SOURCE: Amazon Biotech, Inc

November 16, 2005 16:00 ET

Amazon Biotech, Inc. Announces Appointment of Avraham Harris as Director of Regulatory and Clinical Operations

NEW YORK, NY -- (MARKET WIRE) -- November 16, 2005 -- Amazon Biotech, Inc. (OTC BB: AMZB) announced today the appointment of Avraham Harris as the company's Director of Regulatory and Clinical Operations. Mr. Harris has been in the pharmaceutical field for over 7 years, working in clinical development, consulting, and clinical monitoring roles for pharmaceutical, biotech and clinical research organization (CRO) companies. Mr. Harris has worked for Perio Products, PAREXEL (Lansal) International and R.A.M. Biotechnology Researches, Ltd.

Mr. Harris will oversee the company's drug development program, taking responsibility for protocol development, IND submissions, regulatory contacts, and other related duties.

"I am extremely pleased that Mr. Harris has agreed to be our company's Director of Regulatory and Clinical Operations," said Dr. Kanovsky, President of Amazon Biotech. "Mr. Harris has a strong life science background and is very well versed in dealing with regulatory bodies such as the FDA and its European counterparts. We believe that Mr. Harris will add to our capability to successfully complete our current clinical development plan."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ 0026 is the Company's first such drug, to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ 0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market. Additional information on Amazon Biotech may be found at

Forward-Looking Statements

"Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes,'' "expects,'' "anticipates,'' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information


    LC Group
    Rick Lutz
    (404) 261-1196